Drugs / Trivalent Baculovirus-expressed Influenza HA vaccine
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00307710 | Aug 2004 → Feb 2007 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00307177 | Aug 2004 → Apr 2005 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00766285 | ? → Sep 2010 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trivalent Baculovirus-expressed Influenza HA vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00307710 ↗ |
| Known as | Recombinant rHA0 | “Trivalent Baculovirus-expressed influenza HA vaccine (Recombinant rHA0): Arms B, C and D receive 15 mcg, 45 mcg or 135 mcg IM dose on Day 0.” NCT00307177 ↗ |
| Modality | Vaccine | “experimental influenza vaccine” NCT00307177 ↗ |
| Route | Intramuscular | “via IM injection on Day 0” NCT00307177 ↗ |